Literature DB >> 11933586

Malignant liver tumors.

Angela D Levy1.   

Abstract

The primary hepatic malignancies are a diverse group of neoplasms with distinctive clinical and pathologic features. Imaging of the primary hepatic malignancies continues to be challenging. Ultrasonography, CT scanning, and MR imaging play complementary roles in the evaluation of these patients. Many [figure: see text] of these neoplasms have distinctive imaging features that may permit diagnosis. In most instances, however, biopsy is required for definitive diagnosis and treatment planning.

Entities:  

Mesh:

Year:  2002        PMID: 11933586     DOI: 10.1016/s1089-3261(03)00070-9

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  6 in total

1.  Magnetic Resonance Imaging of cholangiocarcinoma.

Authors:  Katrina A Vanderveen; Hero K Hussain
Journal:  Cancer Imaging       Date:  2004-04-06       Impact factor: 3.909

2.  Focal hepatic lesions in Gd-EOB-DTPA enhanced MRI: the atlas.

Authors:  José Traila Campos; Claude B Sirlin; Jin-Young Choi
Journal:  Insights Imaging       Date:  2012-06-15

3.  Primary hepatic peripheral T-cell lymphoma: A case report.

Authors:  Hui-Juan Hu; Mei-Yan Liao; Yan-Juan Qu
Journal:  Oncol Lett       Date:  2014-05-07       Impact factor: 2.967

4.  Clinical and radiographic observations from four patients with primary hepatic lymphoma.

Authors:  Hui-Juan Hu; Yan-Juan Qu; Zhi-Xiong Tian; Zai-Peng Zhang
Journal:  Exp Ther Med       Date:  2015-12-16       Impact factor: 2.447

5.  Magnetic resonance imaging of liver tumors using gadoxetic acid (Gd-EOB-DTPA) - pilot study.

Authors:  Pola Borusewicz; Ewa Stańczyk; Krzysztof Kubiak; Jolanta Spużak; Kamila Glińska-Suchocka; Marcin Jankowski; Piotr Sławuta; Dominika Kubiak-Nowak; Przemysław Podgórski
Journal:  BMC Vet Res       Date:  2019-08-14       Impact factor: 2.741

Review 6.  Clinical application of 18F-fluorodeoxyglucose positron emission tomography for assessment and evaluation after therapy for malignant hepatic tumor.

Authors:  Masakatsu Tsurusaki; Masahiko Okada; Hiroyuki Kuroda; Mitsuru Matsuki; Kazunari Ishii; Takamichi Murakami
Journal:  J Gastroenterol       Date:  2013-03-26       Impact factor: 7.527

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.